We are live on ! Find out more
CAC

Cowen and Company Portfolio holdings

AUM $2.97B
1-Year Est. Return 105.26%
This Fund
S&P 500
This Quarter Est. Return
+2.81%
1 Year Est. Return
+105.26%
3 Year Est. Return
+120.05%
5 Year Est. Return
+670.56%
10 Year Est. Return
AUM
$2.97B
AUM Growth
-$668M
Cap. Flow
+$51.1M
Cap. Flow %
1.72%
Top 10 Hldgs %
63.58%
Holding
795
New
186
Increased
196
Reduced
157
Closed
179

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$120M
2
LLY icon
Eli Lilly
LLY
+$117M
3
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$70.3M
4
AMZN icon
Amazon
AMZN
+$16.6M
5
PLTR icon
Palantir
PLTR
+$16.1M

Sector Composition

Rank Sector Weight
1 Technology 35.38%
2 Financials 18.11%
3 Healthcare 16.24%
4 Consumer Discretionary 10.31%
5 Communication Services 9.55%

No holdings matched the selected filter criteria.

Similar funds

Cowen and Company's Q3 2024 Portfolio in Review

As of Q3 2024, Cowen and Company held 795 positions worth $2.97B, down 18% from $3.64B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Cowen and Company's Q3 2024 filing shows 186 new, 196 increased, 157 reduced and 179 closed positions. Its largest new stake was Eli Lilly: 130,399 shares worth $116M. The largest sale was Meta Platforms (Facebook), an estimated $239M.

By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 34% a quarter earlier, followed by Financials and Healthcare.

  • Cowen and Company's largest Q3 2024 buy was Eli Lilly: 130,399 shares worth $116M.
  • Cowen and Company added most to Microsoft in Q3 2024, an estimated $120M increase.
  • Cowen and Company's biggest Q3 2024 reduction was Meta Platforms (Facebook), cutting an estimated $239M.
  • Cowen and Company fully exited Avidity Biosciences in Q3 2024, selling an estimated $210M.
  • Cowen and Company's ten largest holdings make up 64% of its $2.97B portfolio in Q3 2024.
  • Cowen and Company opened 186 new positions and closed 179 in Q3 2024.
  • Cowen and Company's portfolio value fell 18% quarter-over-quarter to $2.97B.

Based on Cowen and Company's 13F filing for Q3 2024, filed 12 Nov 2024.